Quote:

---

1) A clear explanation as of why the commercialization deal was not signed: was it them?, us? and if so, why ??? Is the Oncology explanation that NP provided related to pricing issues?
2) Results of 700mg safety data.
3) Has FDA communicated the dosage they want the BLA for ?? If not, when is it expected (any talks with FDA regarding this)??
4) How ready are we to submit BLA once this happens?
5) Any NASH developments in regards to BP "seeing the data ?"
6) What is the road ahead as far as finances go (in light of no commercialization deal signed).

---

That is a good list mine would be: 1)BLA progress, 2) deal explanation 3) financing strategy, then everything else.

everything else:
TNBC, NASH, PrEP

I would also like more info on current mono trial status and new pivotal trial IND, as that is one of their largest expenses.